Feb 2022
Watch the video and download the slides
Prof. Neeraj Agarwal takes a look at poly-ADP ribose polymerase inhibitors (PARPi's) in prostate cancer and in particular the latest clinical developments.
Watch the video and download the slides.
Hi, my name is Dr Neeraj Agarwal. I'm a Professor of Medicine and Director of Genito-Urinary Oncology Program at the Huntsman Cancer Institute, University of Utah in Salt Lake City, United States of America.
Today, I'm going to talk about development of PARP inhibitors, or poly(ADP-ribose) polymerase inhibitors, in the context of advanced prostate cancer.
We know that cells which harbour deficiencies or defects in DNA repair genes, more specifically homologous recombination repair genes, excessively rely on poly(ADP-ribose) polymerase to survive.
In this context, regardless of the tumour types, if we target these cells with inhibitors of PARP enzyme it can lead to lethality in the cells and tumour cell death.
Based on this principle multiple PARP inhibitors have been developed in prostate cancer which have led to approval of two PARP inhibitors, olaparib and rucaparib, in the context of metastatic castration-resistant prostate cancer which has already progressed on novel hormonal therapies such as enzalutamide or abiraterone or novel hormonal therapy and chemotherapy.
So olaparib is approved after disease progression on novel hormonal therapy and rucaparib is approved after disease progression on novel hormonal therapy, as well as chemotherapy with docetaxel.
However, we also know, based on the preclinical data, there is a rationale for developing PARP inhibitors in patients who do not have DNA repair gene mutations in their cancers.
Androgen receptor and PARP seem to have interdependency. Androgen receptor targeting can create a BRCAness phenotype, and PARP inhibitors can make prostate cancer cells excessively reliant or excessively sensitive to targeting by androgen receptor inhibitors based on the preclinical rationale.
Based on this data, two phase 3 trials were reported in the 2022 Genito-Urinary Oncology Symposium, also known as GU ASCO.
MAGNITUDE trial, reporting improved radiographic progression-free survival with the combination of abiraterone and niraparib versus abiraterone with placebo in patients who were biomarker positive who were harbouring DNA repair gene mutations in their cancers. This benefit was most pronounced in those patients with prostate cancer who had BRCA1 and BRCA2 mutations. And we did not see any benefit with this combination in patients who did not have homologous recombination repair gene mutations.
Intriguingly, in the same meeting, PROpel trial was presented, which was also a phase 3 trial with a combination of abiraterone with olaparib showing benefit. Significant improvement in radiographic progression-free survival compared to abiraterone with placebo in patients with metastatic castration-resistant prostate cancer regardless of presence of underlying DNA repair gene mutations.
Both MAGNITUDE trial and the PROpel trial were conducted in the first-line, castration-resistant prostate cancer setting.
We also know that there are two trials going on in metastatic castration-sensitive prostate cancer in patients who are harbouring DNA repair gene mutations in their tumours.
In the AMPLITUDE trial, the combination of abiraterone and niraparib is being tested against abiraterone plus placebo.
In the TALAPRO-3 trial, the combination of enzalutamide with talazoparib is being tested compared to enzalutamide plus placebo. The endpoint in both trials is radiographic progression-free survival.
Time will tell if these trials are positive and if they are PARP inhibitors will continue to move up in the setting of advanced prostate cancer.
Please also refer to the enclosed slides which have been uploaded with this talk highlighting the role of PARP inhibitors in advanced prostate cancer. Thank you very much for your kind attention.
Neeraj Agarwal, MD, is a Professor in the Division of Oncology, Department of Medicine, at the University of Utah School of Medicine. He is the Senior Director for Clinical Research Innovation at Huntsman Cancer Institute, and the HCI Presidential Endowed Chair of Cancer Research. He also serves as the Director of the Genitourinary Oncology Program at the Huntsman Cancer Institute, Salt Lake City, Utah, and directs the Center of Investigational Therapeutics and co-leads the “Experimental Therapeutic Program” at HCI. As a specialist in adult hematology and oncology, Dr Agarwal cares for patients with all types of cancer and specializes in genitourinary malignancies (cancers of the prostate, kidney, bladder and testes). Dr Agarwal is a member of several professional societies, including the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR) and the Southwest Oncology Group (SWOG). After receiving his MD degree from All India Institute of Medical Sciences in New Delhi, India, Dr Agarwal completed a residency in internal medicine and a fellowship in geriatric medicine at the University of Iowa. He then completed a hematology-oncology fellowship at HCI and the University of Utah School of Medicine. Dr Agarwal has received several awards and grants and has authored more than 300 peer-reviewed articles and book chapters. He has given talks at several prestigious regional and national forums and serves as a panel member for the NCCN guideline-committees for bladder and kidney cancer. Dr Agarwal also serves as the overall study chair and/or steering committee member of multiple national and international clinical trials in GU cancers. Dr Agarwal has the prestigious honor of being chosen as one of the five young investigators of the Southwest Oncology Group in 2009. He has been appointed as the leader of early therapeutics of the SWOG Genitourinary Cancer Committee in 2010. Dr Agarwal is also the recipient of the prestigious 2009-2010 William D. Odell Young Investigator award from the University of Utah’s, Department of Medicine, and the 2014 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute.
Arnivas, Astellas, AstraZeneca, Bavarian Nordic , Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, GSK, Immunomedics, Janssen, Lava, Medivation, Merck, Nektar, Neoleukin, New Link Genetics, Novartis, Oric, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon.
Module 2 - Evolving landscape of PARPi in mCRPC: Combination with anti-androgens
Downloadable 
4 MIN
Oct 2023 
Prof. Neeraj Agarwal takes a look at poly-ADP ribose polymerase inhibitors (PARPi's) in prostate cancer and in particular the latest clinical developments.
Downloadable
5 MIN
Feb 2022
Downloadable
MIN
Jan 2022
Downloadable
MIN
Jan 2022
Downloadable
MIN
Jan 2022
GU CONNECT has developed a comprehensive resource which is available on ESMO OncologyPRO, providing information on PARP inhibitors in prostate cancer
30 MIN
Dec 2021
Duration 5 MIN
Downloadable resources Yes
DOWNLOAD SLIDES - PPT
DOWNLOAD SLIDES - PDF
Language(s)
Video
Two emerging and two established targets
Downloadable
4 MIN
Dec 2024 
Publication
Announcing the publication of survey results
Downloadable
10 MIN
Dec 2024 
Video
An expert overview of the EMERALD subgroup analysis
Downloadable
4 MIN
Dec 2024 
Video
Managing patients with nccRCC: guidelines, recommendations, and best practice
Downloadable
4 MIN
Dec 2024
Micro learning
Risk factors, diagnostic tools and treatment options for different patient groups
Downloadable
4 MIN
Dec 2024 
Conference update
Exploring emerging treatment strategies presented at SABCS 2024
Downloadable
5 MIN
Dec 2024
